AstraZeneca's trial illnesses may not be due to Covid-19 shot
Coronavirus chronicle
16 September, 2020, 10:20 pm
Last modified: 16 September, 2020, 10:21 pm
Britain's Medicines and Healthcare products Regulatory Agency (MHRA) started an accelerated "rolling review" of the vaccine at the start of this month as data comes in on safety and efficacy. Photo: Reuters
The adverse events that led to a pause in trials evaluating AstraZeneca Plc's Covid-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted online by the Oxford University.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.